Table 3.
Patient No. | Time point | Titer | ||
Anti-Vaccinia | Anti-Fowlpox | Anti-CEA | ||
002-001 | Day 0 | 1600 | 200 | NDa |
Day 14 | 6400 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | <100 | |
Day 70 | - | 3200 | <100 | |
Extension Phase Month 1b | - | - | <100 | |
Extension Phase Month 2 | - | - | <100 | |
002-002 | Day 0 | 1600 | <100 | ND |
Day 14 | 3200 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | <100 | |
Day 63 | - | 1600 | <100 | |
002–003 | Day 0 | 400 | <100 | ND |
Day 14 | 1600 | - | <100 | |
Day 28 | - | <100 | <100 | |
Day 36 | - | - | ND | |
002–005 | Day 0 | 200 | <100 | ND |
Day 14 | 800 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | 100 | |
Day 70 | - | 400 | <100 | |
002–006 | Day 0 | 200 | <100 | ND |
Day 14 | 800 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | 3200 | |
Day 70 | - | 800 | 800 | |
Extension Phase Month 2 | - | - | 800 | |
Extension Phase Month 3 | - | - | 400 | |
002–007 | Day 0 | <100 | 200 | ND |
Day 14 | 200 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | 100 | |
Day 70 | - | 800 | 100 | |
Extension Phase Month 2 | - | - | <100 | |
Extension Phase Month 3 | - | - | <100 | |
Extension Phase Month 4 | - | - | <100 | |
Extension Phase Month 5 | - | - | <100 | |
Extension Phase Month 6 | - | - | <100 | |
Extension Phase Month 7 | - | - | <100 | |
Extension Phase Month 8 | - | - | <100 | |
Extension Phase Month 9 | - | - | <100 | |
001–008 | Day 0 | 800 | <100 | ND |
Day 14 | 6400 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | 3200 | <100 | |
001–009 | Day 0 | 800 | <100 | ND |
Day 14 | 800 | - | <100 | |
Day 28 | - | <100 | <100 | |
001–010 | Day 0 | 400 | <100 | ND |
Day 14 | 1600 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | 100 | 100 | |
001–011 | Day 0 | 1600 | 100 | ND |
Day 14 | 1600 | - | <100 | |
Day 28 | - | - | <100 | |
Day 42 | - | - | <100 | |
Day 70 | - | 800 | 200 | |
Extension Phase Month 2 | - | - | 100 |
Bolded values indicate development of antibody response, which is defined as a 2-fold increase in titer of the post-immunization sample as compared to the corresponding negative control sample. aND: not determined. Because the time 0 sample is the negative control sample for the CEA ELISA, a titer cannot be assigned to this sample. bFor this patient, the sample collected approximately 2 weeks after the day 70 vaccination was labeled "Extension Phase Month 1"; for all other patients, the sample collected one month after the day 70 vaccination was labeled "Extension Phase Month 2".